search
Back to results

Neural Correlates of Repeated tDCS

Primary Purpose

Mild Cognitive Impairment

Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
active tDCS
sham tDCS
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Mild Cognitive Impairment focused on measuring tDCS, Mild Cognitive Impairment, fMRI, Healthy ageing

Eligibility Criteria

60 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Patients

  • Diagnosis of MCI based on the latest research criteria (clinical assessment at the memory clinic (prof. Frans RJ Verhey): presence of at least a memory impairment, memory complaints expressed by the patient or informant, no problems in daily life functioning, no dementia and presence of biomarkers (Albert et al., 2011)
  • Clinical Dementia Rating score of 0.5 (CDR distinguishes a stage of questionable dementia (CDR 0.5) from people termed healthy (CDR 0) and those with mild dementia (CDR 1)
  • Mini-Mental State Examination (MMSE) 23 and being mentally competent (in general, individuals with a MMSE 18 are considered mentally competent)
  • Age: between 60 and 85 years old
  • 50% female
  • Right-handedness
  • Average level of education (CBS level 3-4-5-6)

Healthy controls

  • Average neuropsychological test results, in accordance with normative data, corrected for age, education and gender
  • No substantial memory complaints (according to the participant)
  • Age: between 60 and 85 years old
  • 50% female
  • Right-handedness
  • Average level of education (CBS level 3-4-5-6)
  • Normal or corrected to normal vision

Exclusion Criteria:

  • Psychoactive medication use
  • Abuse of alcohol and drugs
  • Cognitive impairment due to alcohol/drug abuse or abuse of other substances
  • Past or present psychiatric or neurological disorders (major depression, schizophrenia, bipolar disorder, psychotic disorder (or treatment for it), epilepsy, stroke, Parkinson's disease, multiple sclerosis, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Menière's disease, brain infections)
  • Major vascular disorders (e.g. stroke)
  • Heart diseases or pacemakers
  • Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, body tattoos)
  • Large scars or fresh wounds on the scalp

Sites / Locations

  • Maastricht UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Sham Comparator

Experimental

Sham Comparator

Arm Label

MCI-active

MCI-sham

Healthy Old-active

Healthy old-sham

Arm Description

Patients will receive verum tDCS over the angular gyrus on five consecutive days.

Patients will receive sham tDCS over the angular gyrus on five consecutive days.

Participants will receive verum tDCS over the angular gyrus on five consecutive days.

Participants will receive sham tDCS over the angular gyrus on five consecutive days.

Outcomes

Primary Outcome Measures

neural changes after multi-session tDCS
fMRI-BOLD response
network changes after multi-session tDCS
functional connectivity between network hubs

Secondary Outcome Measures

Task performance changes after multi-session tDCS
BPS-score

Full Information

First Posted
November 23, 2016
Last Updated
March 22, 2018
Sponsor
Maastricht University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02997007
Brief Title
Neural Correlates of Repeated tDCS
Official Title
Investigating the Neural Correlates of Repeated tDCS in MCI and Healthy Ageing With fMRI
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Unknown status
Study Start Date
May 2, 2017 (Actual)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Healthy ageing and pathological ageing in the context of a neurodegenerative disease are both associated with changes in brain network integrity. Episodic memory is especially affected in Alzheimer's disease, but is also decreased in healthy ageing. Consequently, the memory-relevant brain networks are especially altered. Transcranial direct current stimulation (tDCS) has previously been implemented in different clinical- and non-clinical settings and has shown to beneficially influence network connectivity. The neural correlates of single-session tDCS have been investigated, however, the neural effects of repeated tDCS remain unknown. Furthermore, knowledge about the (long-term) neural mechanisms of repeated tDCS can give valuable insights and possibly pave the ground for exploring tDCS as a treatment option in future studies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild Cognitive Impairment
Keywords
tDCS, Mild Cognitive Impairment, fMRI, Healthy ageing

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
MCI-active
Arm Type
Experimental
Arm Description
Patients will receive verum tDCS over the angular gyrus on five consecutive days.
Arm Title
MCI-sham
Arm Type
Sham Comparator
Arm Description
Patients will receive sham tDCS over the angular gyrus on five consecutive days.
Arm Title
Healthy Old-active
Arm Type
Experimental
Arm Description
Participants will receive verum tDCS over the angular gyrus on five consecutive days.
Arm Title
Healthy old-sham
Arm Type
Sham Comparator
Arm Description
Participants will receive sham tDCS over the angular gyrus on five consecutive days.
Intervention Type
Device
Intervention Name(s)
active tDCS
Intervention Description
Participants will receive active tDCS over the angular gyrus on five consecutive days
Intervention Type
Device
Intervention Name(s)
sham tDCS
Intervention Description
Participants will receive sham tDCS over the angular gyrus on five consecutive days
Primary Outcome Measure Information:
Title
neural changes after multi-session tDCS
Description
fMRI-BOLD response
Time Frame
5-12 days
Title
network changes after multi-session tDCS
Description
functional connectivity between network hubs
Time Frame
5-12 days
Secondary Outcome Measure Information:
Title
Task performance changes after multi-session tDCS
Description
BPS-score
Time Frame
5-12 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients Diagnosis of MCI based on the latest research criteria (clinical assessment at the memory clinic (prof. Frans RJ Verhey): presence of at least a memory impairment, memory complaints expressed by the patient or informant, no problems in daily life functioning, no dementia and presence of biomarkers (Albert et al., 2011) Clinical Dementia Rating score of 0.5 (CDR distinguishes a stage of questionable dementia (CDR 0.5) from people termed healthy (CDR 0) and those with mild dementia (CDR 1) Mini-Mental State Examination (MMSE) 23 and being mentally competent (in general, individuals with a MMSE 18 are considered mentally competent) Age: between 60 and 85 years old 50% female Right-handedness Average level of education (CBS level 3-4-5-6) Healthy controls Average neuropsychological test results, in accordance with normative data, corrected for age, education and gender No substantial memory complaints (according to the participant) Age: between 60 and 85 years old 50% female Right-handedness Average level of education (CBS level 3-4-5-6) Normal or corrected to normal vision Exclusion Criteria: Psychoactive medication use Abuse of alcohol and drugs Cognitive impairment due to alcohol/drug abuse or abuse of other substances Past or present psychiatric or neurological disorders (major depression, schizophrenia, bipolar disorder, psychotic disorder (or treatment for it), epilepsy, stroke, Parkinson's disease, multiple sclerosis, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Menière's disease, brain infections) Major vascular disorders (e.g. stroke) Heart diseases or pacemakers Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, body tattoos) Large scars or fresh wounds on the scalp
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lisa Müller-Ehrenberg, MSc
Phone
0031433881025
Email
l.muller-ehrenberg@maastrichtuniversity.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Heidi IL Jacobs, PhD
Phone
0031433884090
Email
h.jacobs@maastrichtuniversity.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Heidi IL Jacobs, PhD
Organizational Affiliation
Maastricht University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Frans RJ Verhey, Professor
Organizational Affiliation
Maastricht University
Official's Role
Study Chair
Facility Information:
Facility Name
Maastricht University
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6221ET
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lisa Müller-Ehrenberg, MSc
Phone
0031433881025
Email
l.muller-ehrenberg@maastrichtuniversity.nl

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Neural Correlates of Repeated tDCS

We'll reach out to this number within 24 hrs